Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apremilast + methotrexate
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
apremilast + methotrexate is a combination therapy consisting of the phosphodiesterase-4 (PDE4) inhibitor apremilast and the folate antimetabolite methotrexate. This combination is being investigated in clinical trials, such as those conducted by Tanta University, for the treatment of psoriatic arthritis. Apremilast works by inhibiting PDE4, which increases intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating the expression of various pro-inflammatory and anti-inflammatory mediators. Methotrexate acts by inhibiting dihydrofolate reductase (DHFR) and other folate-dependent enzymes, leading to the inhibition of DNA synthesis and cellular proliferation, as well as exerting anti-inflammatory effects through the release of adenosine. The combination aims to provide synergistic or additive therapeutic benefits in managing the symptoms and progression of psoriatic arthritis.
- Brand names
- OtezlaRheumatrexTrexall
- Other names
- MTX
02
Targets
DHFR (Dihydrofolate reductase)PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on apremilast + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apremilast + methotrexate.